A practical reference on incretin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
In the morning of 8 October, Hezbollah fired rockets and shells at the Shebaa Farms region in support of Hamas's attack onto Israel; in response, the Israel Defense Forces (IDF) fired artillery shells and a drone into southern Lebanon. Two Lebanese children were reportedly injured by broken glass. The next day, Israel exchanged a series of airstrikes on southern Lebanon near the towns of Marwahin, Ayta ash Shab and Dhayra in the Bint Jbeil district. This was after numerous Palestinian militants infiltrated the Israeli border, which Hezbollah denied involvement with. The Palestinian Islamic Jihad militia claimed responsibility for the armed infiltration. The IDF killed at least two perpetrators (likely Palestinians), while a third returned to Lebanon. A Hezbollah media source announced three of Hezbollah's members died in the IDF retaliation. Hezbollah fired rockets and artillery in retaliation. During the clashes, two Israeli soldiers and Lt. Col Alim Abdallah, Deputy Commander of the IDF's 300th Brigade, were killed and another three were wounded. On 11 October, Hezbollah fired anti-tank missiles at an IDF position and claimed to have produced casualties. In response, the IDF shelled the area where the attack was launched. The Lebanese-Italian hospital in Tyre admitted three injured civilians. The IDF ordered residents of northern Israel to seek shelter following reports of drones being launched from southern Lebanon. A Patriot missile was launched to intercept a suspicious projectile, after which the IDF found that the object in question was not a drone.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{238}_{92}U->[\alpha ][4.463\times 10^{9}\ {\ce {y}}]{^{234}_{90}Th}->[\beta ^{-}][24.11\ {\ce {d}}]{^{234\!m}_{91}Pa}}}{\begin{Bmatrix}{\ce {->[0.16\%][1.16\ {\ce {min}}]{^{234}_{91}Pa}->[\beta ^{-}][6.70\ {\ce {h}}]}}\\{\ce {->[99.84\%\ \beta ^{-}][1.16\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{234}_{92}U->[\alpha ][2.455\times 10^{5}\ {\ce {y}}]{^{230}_{90}Th}->[\alpha ][7.54\times 10^{4}\ {\ce {y}}]{^{226}_{88}Ra}->[\alpha ][1600\ {\ce {y}}]{^{222}_{86}Rn}}}\\{\ce {^{222}_{86}Rn->[\alpha ][3.8235\ {\ce {d}}]{^{218}_{84}Po}->[\alpha ][3.097\ {\ce {min}}]{^{214}_{82}Pb}->[\beta ^{-}][27.06\ {\ce {min}}]{^{214}_{83}Bi}->[\beta ^{-}][19.9\ {\ce {min}}]{^{214}_{84}Po}->[\alpha ][164.3\ \mu {\ce {s}}]{^{210}_{82}Pb}->[\beta ^{-}][22.2\ {\ce {y}}]{^{210}_{83}Bi}->[\beta ^{-}][5.012\ {\ce {d}}]{^{210}_{84}Po}->[\alpha ][138.376\ {\ce {d}}]{^{206}_{82}Pb}}}\end{array}}}
== External links == "Gonadotrophin-Releasing Hormone Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-04. GNRHR+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Gone with the Wind—first released in 1939—is generally considered to be the most successful film, with Guinness World Records in 2014 estimating its adjusted global gross at $3.4 billion. Estimates for Gone with the Wind's adjusted gross have varied substantially: its owner, Turner Entertainment, estimated its adjusted earnings at $3.3 billion in 2007, a few years earlier than the Guinness estimate; other estimates fall either side of this amount, with one putting its gross just under $3 billion in 2010, while another provided an alternative figure of $3.8 billion in 2006. Which film is Gone with the Wind's nearest rival depends on the set of figures used: Guinness had Avatar in second place with $3 billion, while other estimates saw Titanic in the runner-up spot with first-run worldwide earnings of almost $2.9 billion at 2010 prices.
== Early life and education == Rudolf Schoenheimer was born in Berlin, Germany on 10 May 1898. He was the son of Gertrude Edel and Hugo Schoenheimer, who was a physician. He was Jewish, however his family converted to Christianity. He attended local schools in Berlin before graduating from the Dorotheen-Stadtische Gymnasium in 1916. Following his graduation Schoenheimer was drafted into the German army. He served in the artillery on the western front for two years during world war 1. Following his service in the war, he began his study of medicine at the University of Berlin. In 1922 he received his M.D. His M.D dissertation was titled "Über die experimentelle Cholesterinkrankheit der Kaninchen" ("About the experimental cholesterol disease of rabbits"). He then spent a year working at the Moabit Hospital in Berlin as a pathologist. He continued his scientific research during this time and studied the production of atherosclerosis in animals through administering cholesterol. In 1924, Schoenheimer began his 3-year study at the University of Leipzig, in a program aimed at advancing his knowledge in chemistry. The program was aided by the Rockefeller Foundation and taught by Karl Thomas, professor of physiological chemistry at the University of Leipzig. During his time at Leipzig, Schoenheimer was able to develop a method of synthesising peptides.
The report published by the committee noted that while methadone itself was potentially addictive, it produced "considerably" less euphoria, sedation, and respiratory depression than morphine at equianalgesic doses and was thus interesting as a commercial drug. The same report also compared methadone to pethidine. German researchers reported that methadone was capable of producing strong morphine-like physical dependence, which is characterized by opioid withdrawal symptoms which are lesser in severity and intensity compared to morphine, but methadone was associated with a considerably prolonged or protracted withdrawal syndrome when compared to morphine. Morphine produced higher rates of self-administration and reinforcing behaviour in both human and animal subjects when compared to both methadone and pethidine. In comparison to equianalgesic doses of pethidine (Demerol), methadone was shown to produce less euphoria, but higher rates of constipation, and roughly equal levels of respiratory depression and sedation. In the early 1950s, methadone (most times the racemic HCl salts mixture) was also investigated for use as an antitussive. Isomethadone, noracymethadol, LAAM, and normethadone were first developed in Germany, the United Kingdom, Belgium, Austria, Canada, and the United States in the thirty or so years after the 1937 discovery of pethidine, the first synthetic opioid used in medicine.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.